Search
Desmopressin
go.drugbank.com/drugs/DB00035ApprovedInvestigationalIt was designed through two primary chemical modifications of the natural hormone: the deamination of 1-cysteine and the substitution of L-arginine with D-arginine at the 8th position [A31661, A275458] … First synthesized in the 1960s, desmopressin has remained a gold-standard therapy for water balance disorders due to its safety and long duration of action compared to natural AVP [A31661, A275461].
Interferon alfa-2b
go.drugbank.com/drugs/DB00105ApprovedInvestigationalInterferon alpha 2b (human leukocyte clone hif-sn 206 protein moiety reduced). A type I interferon consisting of 165 amino acid residues with arginine in position 23. This protein is produced by recombinant DNA technology and resembles i...
Mixtures: Rebetron Ready To Use Solution (albumin(human)free) (6000000 Iu/ml and 200mg Capsules)Garetosmab
go.drugbank.com/drugs/DB16379ApprovedInvestigational[L63940] It is a fully human IgG4 monoclonal antibody that binds and neutralizes activin A, blocking activin A from activating the mutant ACVR1 receptor that, in FOP, drives the formation of heterotopic … [L63940] Garetosmab-grts was approved by the FDA on August 19, 2026 to reduce the number of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with FOP.
Linzagolix
go.drugbank.com/drugs/DB17083ApprovedInvestigationalLinzagolix is a non-peptide, selective antagonist of the gonadotropin-releasing hormone (GnRH) receptor. … [A253642,A253647] It is similar to other GnRH receptor antagonists like [cetrorelix], [relugolix], and [elagolix].
Categories: Gonadotropin Releasing Hormone Receptor AntagonistsBelimumab
go.drugbank.com/drugs/DB08879ApprovedInvestigational[L42630] Belimumab was first approved by the FDA on March 9, 2011,[A251495] making it the newest drug to be approved for the treatment of SLE in more than 50 years. … [A251495, L42705] By binding to BLyS and blocking its interaction with B cell receptors, belimumab inhibits the survival of B cells.
Orlistat
go.drugbank.com/drugs/DB01083ApprovedInvestigationalThe global prevalence of obesity is increasing rapidly. … Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare.
Plasma protein fraction (human)
go.drugbank.com/drugs/DB13968ApprovedInvestigational[A32512] It is already reviewed under the category of biologics by the FDA where the processing, required tests, requirements and labeling are incorporated. … The composition of PPFh should be 5% of protein from which 83% should consist of albumin and no more of 17% should be globulin.
Guselkumab
go.drugbank.com/drugs/DB11834ApprovedInvestigationalIL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation [A20357]. … Developed by Janssen, the subcutenous injection form of guselkumab was approved in July 2017 under the market name Tremfya for the treatment of adult patients with moderate-to-severe plaque psoriasis.
Miglitol
go.drugbank.com/drugs/DB00491ApprovedMiglitol should be taken at the start of a meal for maximal effect and the effect will depend on the amount of poly and oligosaccharides in the diet. … monosaccharides which can be absorbed by the body.
Anthrax vaccine
go.drugbank.com/drugs/DB11003ApprovedInvestigational[L47526] It is considered one of the most likely agents to be used in a biological attack. … around the world.